MAAT INDEX

CLAIM #3743 · Accenture plc (ACN) · 2025Q1 earnings call · Dec 19, 2024 · due Mar 31, 2025

Looking ahead, we'll continue to hire for the demand that we see and the skills that we need.

Angie Park · CFO

PENDING
graded after results covering Mar 31, 2025 are reported

In context

raising the guidance. Jason Kupferberg: Great to hear. And then I'm just looking at the net headcount adds cumulatively over the past two quarters. I think we're almost 50,000. That was a pretty big step up from what the prior trend looked like. So can you give us any sense of how much of that was from acquisitions versus organic? And I guess is there any reason to not look at this accelerated hiring as kind of a bullish indicator? Angie Park: So let me take that question. And as it relates to the net people adds that we had in Q1. So we did add about 24,000 people in the first quarter, which is really reflective of the momentum that we see in our business. And managing supply and demand is a core competency of ours. And what you see is the continued high utilization rates at around 90%. Looking ahead, we'll continue to hire for the demand that we see and the skills that we need. And I'll give you a little bit more context that the hiring that we saw this quarter, similar to last was that it was concentrated in India. Julie Sweet: Yes. And I would just say that underlying our guidance, you are seeing organic momentum, right? So at the high-end of our guidance, for the year, we are going to exit at -- the range of organic growth in our guidance is 1 to 4, right? So I think that is -- it is a positive sign that we're hiring and some of it is coming from acquisitions, but we are seeing organic momentum in our business. Jason Kupferberg : Thanks for the comments. Operator: Thank you. And our next question comes from Bryan Keane with Deutsche Bank. Please go ahead. Bryan Keane: Hi guys. Congrats on the solid result. And Happy holidays. Kind of asking the guidance quest

Verify independently

SEC filings for ACN · Claim quote is verbatim from the 2025Q1 earnings call.